



**Recipient Information**

**1. Recipient Name**

Missouri Department of Health  
920 WILDWOOD DR  
Community and Public Health  
JEFFERSON CITY, MO 65109-5796  
[NO DATA]

**2. Congressional District of Recipient**

03

**3. Payment System Identifier (ID)**

[REDACTED]

**4. Employer Identification Number (EIN)**

[REDACTED]

**5. Data Universal Numbering System (DUNS)**

878092600

**6. Recipient's Unique Entity Identifier**

**7. Project Director or Principal Investigator**

Ms. Christine Smith  
CO - Principal Investigator  
christine.smith@health.mo.gov  
573-751-6439

**8. Authorized Official**

Ms. Marcia A Mahaney  
Director  
Marcia.Mahaney@health.mo.gov  
573-751-6014

**Federal Agency Information**

CDC Office of Financial Resources

**9. Awarding Agency Contact Information**

Ms. Valerie McCloud  
Grants Management Specialist  
fyq4@cdc.gov  
770.488.4790

**10. Program Official Contact Information**

Mr. Mark Hogan  
Public Health Analyst  
vjn5@cdc.gov  
404-718-8741

**Federal Award Information**

**11. Award Number**

1 NU51PS005156-01-00

**12. Unique Federal Award Identification Number (FAIN)**

NU51PS005156

**13. Statutory Authority**

PHS ACT, SECT. 318 (42U.S.C. SEC 247C)

**14. Federal Award Project Title**

Missouri Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments

**15. Assistance Listing Number**

93.270

**16. Assistance Listing Program Title**

Adult Viral Hepatitis Prevention and Control

**17. Award Action Type**

New

**18. Is the Award R&D?**

No

**Summary Federal Award Financial Information**

<b>19. Budget Period Start Date</b>	05/01/2021	- End Date	04/30/2022
<b>20. Total Amount of Federal Funds Obligated by this Action</b>			\$257,824.00
20a. Direct Cost Amount			\$207,650.00
20b. Indirect Cost Amount			\$50,174.00
<b>21. Authorized Carryover</b>			\$0.00
<b>22. Offset</b>			\$0.00
<b>23. Total Amount of Federal Funds Obligated this budget period</b>			\$0.00
<b>24. Total Approved Cost Sharing or Matching, where applicable</b>			\$0.00
<b>25. Total Federal and Non-Federal Approved this Budget Period</b>			\$257,824.00
<b>26. Project Period Start Date</b>	05/01/2021	- End Date	04/30/2026
<b>27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period</b>			Not Available

**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

**29. Grants Management Officer - Signature**

Mr. Arthur Lusby  
Grants Management Officer, Team Lead

**30. Remarks**

New Award: Financial Assistance awarded in the amount of \$257,824.



Award# 1 NU51PS005156-01-00

FAIN# NU51PS005156

Federal Award Date: 04/21/2021

<p><b>Recipient Information</b></p> <p><b>Recipient Name</b> Missouri Department of Health 920 WILDWOOD DR Community and Public Health JEFFERSON CITY, MO 65109-5796 [NO DATA]</p> <p><b>Congressional District of Recipient</b> 03</p> <p><b>Payment Account Number and Type</b> [REDACTED]</p> <p><b>Employer Identification Number (EIN) Data</b> [REDACTED]</p> <p><b>Universal Numbering System (DUNS)</b> 878092600</p> <p><b>Recipient's Unique Entity Identifier</b> Not Available</p>
<p><b>31. Assistance Type</b> Cooperative Agreement</p> <p><b>32. Type of Award</b> Other</p>

<b>33. Approved Budget</b> (Excludes Direct Assistance)	
I. Financial Assistance from the Federal Awarding Agency Only	
II. Total project costs including grant funds and all other financial participation	
a. Salaries and Wages	\$135,868.00
b. Fringe Benefits	\$0.00
c. Total Personnel Costs	\$135,868.00
d. Equipment	\$0.00
e. Supplies	\$0.00
f. Travel	\$0.00
g. Construction	\$0.00
h. Other	\$71,782.00
i. Contractual	\$0.00
<b>j. TOTAL DIRECT COSTS</b>	<b>\$207,650.00</b>
<b>k. INDIRECT COSTS</b>	<b>\$50,174.00</b>
<b>l. TOTAL APPROVED BUDGET</b>	<b>\$257,824.00</b>
<b>m. Federal Share</b>	<b>\$257,824.00</b>
<b>n. Non-Federal Share</b>	<b>\$0.00</b>

**34. Accounting Classification Codes**

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390C2C	21NU51PS005156	PS	41 51	\$33,898 00	75-21-0950
1-9390E3N	21NU51PS005156	PS	41 51	\$3,395 00	75-75-X-0512-009
1-9390EVQ	21NU51PS005156	PS	41 51	\$81,571 00	75-21-0950
1-9390GDH	21NU51PS005156	PS	41 51	\$97,511 00	75-21-0950
1-939ZRPQ	21NU51PS005156	PS	41 51	\$32,967 00	75-21-0950
1-939ZSEH	21NU51PS005156	PS	41 51	\$8,482 00	75-21-0949



**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 1 NU51PS005156-01-00

FAIN# NU51PS005156

Federal Award Date: 04/21/2021

**Direct Assistance**

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

# AWARD ATTACHMENTS

Missouri Department of Health

1 NU51PS005156-01-00

---

1. T&C for this Notice of Award

**Notice of Funding Opportunity (NOFO): PS21-2103**

**Recipient: Missouri Department of Health**

**Award # NU51PS005156-01-00**

**AWARD INFORMATION**

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS21-2103**, entitled **Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$257,824** is approved for the **Year 01** budget period, which is **May 1, 2021** through **April 30, 2022**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

**Component Funding:** The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

<b>NOFO Component</b>	<b>Amount</b>
<b>Component 1</b>	<b>\$142,824</b>
<b>Component 2</b>	<b>\$115,000</b>
<b>Component 3</b>	<b>\$0</b>
<b>Total Amount of Funding</b>	<b>\$257,824</b>

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

In a cooperative agreement, CDC staff are substantially involved in the program activities, above and beyond routine grant monitoring. CDC activities for this program are as follows:

- Collaborate to ensure coordination and implementation of strategies to support the Implementation of comprehensive viral hepatitis surveillance and prevention activities

- Provide guidance and coordination to funded organizations to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations.
- Collaborate to ensure coordination and provide policy and program information for rapid dissemination and implementation.
- Work with recipients to identify and address capacity building assistance (CBA) and TA needs that are essential to the success of the project.
- Provide access to training and TA that will strengthen staff capacity relevant to all required strategies and activities of the program.
- Provide guidance to the recipient and set standards on data collection, use, and submission requirements.
- Provide guidance and technical assistance in implementing the Hepatitis Message Mapping Guide (MMG) and facilitate collaborations with CSELS to transition to HL7 based case reporting to CDC through the NNDSS
- Provide technical advice in the development of systems to implement and advance CDC policies, initiatives, and programs.
- Collaborate to ensure coordination and implementation of technical assistance services to state and local health department viral hepatitis program staff.
- Collaborate in assessing progress toward meeting goals/outcomes and in establishing measurement and accountability systems for documenting outcomes, such as increased performance improvements and best or promising practices.
- Provide guidance and coordinate with the recipient to improve the quality and effectiveness of the proposed program. This may include revision of the work plan, evaluation strategy, products, and services, among others.
- Foster and support ongoing opportunities for networking, communication, coordination, and collaboration.
- Provide consultation in planning, operating, analyzing, and evaluating viral hepatitis programs, including viral hepatitis elimination planning, CDC special initiatives, (e.g., program integration, viral hepatitis elimination, and program evaluation activities.)
- Monitor recipient program performance using multiple approaches, such as standardized review of performance, recipient feedback and other data reports, to support program development, implementation, evaluation, and improvement.
- Provide support and facilitate program collaboration with other CDC programs and HHS offices to enhance and improve integration of services.
- Assist in assessing program operations and in evaluating overall effectiveness of programs.
- Provide capacity building assistance where identified or as needed to the recipient.
- Collect and disseminate information, best practices, lessons learned, and evaluation results (e.g., through conferences, guidance, material development, webinars, data sharing publications, other social media, participation in meetings, committees, and working groups related to the cooperative agreement).
- Provide requirements and expectations for standardized and other data reporting and support monitoring and evaluation activities.

**Budget Revision Requirement:** By **June 1, 2021** the recipient must submit a revised budget with a narrative justification in support of the activities entitled **Component 1, Component 2, Component 3**. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date. The Budget Revision is a prior approval submitted in **Grant Solutions** as an **amendment**. Please ensure the revised budget includes the following:

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

- ☒ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 “Remarks” of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient’s authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

## FUNDING RESTRICTIONS AND LIMITATIONS

**Notice of Funding Opportunity (NOFO) Restrictions:** Restrictions that must be considered while planning the programs and writing the budget are:

- Recipients may not use funds for research.
- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
  - o publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
  - o the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body

- See [Additional Requirement \(AR\) 12](#) for detailed guidance on this prohibition and [additional guidance on lobbying for CDC recipients](#).
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability <https://www.cdc.gov/grants/additional-requirements/ar-35.html>.

Funds cannot be used to purchase drugs and/or vaccine. Recipients may not use funds to purchase sterile needles or syringes for drug injection.

Funds can be used to purchase hepatitis testing kits, laboratory equipment, and /or contracts in accordance with NOFO. Funds can be used to support SSPs consistent with guidance in this NOFO if a Determination of Need is in place for the jurisdiction. See: <https://www.cdc.gov/ssp/determination-of-need-for-ssp.html>

### **Indirect Costs:**

Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 17, 2020, which calculates indirect costs as follows, a Provisional Rate is approved at a rate of 20.10% of the base, which includes, Direct salaries and wages including all fringe benefits. . The effective dates of this indirect cost rate are from July 1, 2020 to June 30, 2023.

## **REPORTING REQUIREMENTS**

**Performance Progress and Monitoring:** Performance information collection initiated under this cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, “Performance Progress and Monitoring Report”, Expiration Date 10/31/2022.** The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:  
 CDC, Office of Grants Services  
 Valerie McCloud, Grants Management /Specialist



Centers for Disease Control and Prevention  
Branch 1  
Office of Grants Services  
Centers for Disease Control and Prevention (CDC)  
Fax:770-488-4790 (Include "Mandatory Grant Disclosures" in subject line)  
Email:vmccloud@cdc.gov(Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### **PROGRAM OR FUNDING GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula, and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

#### **PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.*

**Payment Management System Subaccount:** Funds awarded in support of approved activities

have been obligated in a subaccount in the PMS, herein identified as the **P Account**". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2, item 34** of the Notice of Award must be known in order to draw down funds.

### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**GMS Contact:**

Valerie McCloud, Grants Management /Specialist  
Centers for Disease Control and Prevention  
Branch 1  
Office of Grants Services  
Centers for Disease Control and Prevention (CDC)  
Fax:770-488-4790  
Email:vmcccloud@cdc.

**Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

**Programmatic Contact:**

Mark Hogan, Project Officer  
Centers for Disease Control and Prevention  
Corporate Square, Building 12 Rm 3225  
MS US12-3  
Atlanta GA 30329  
Telephone:404-718-3722  
Fax: 404-718-3722  
Email: MHogan@CDC.GOV

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

**GMO Contact:**

Arthur C. Lusby  
Grants Management Officer  
Centers for Disease Control and Prevention  
Office of Grants Services  
Infectious Disease Services Branch  
2920 Brandywine Road, NE, MS E-15  
Atlanta, GA 30341-4146  
Phone: (770) 488-2865  
Email: [ALusby@cdc.gov](mailto:ALusby@cdc.gov)

